

Product Datasheet

ErSO-DFP

Catalog No. **BP-02405** · CAS **2768139-76-8** · Form **free base** · Physical state **solid** · Color **White to pink** · Version **1.0** ·
Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Estrogen Receptor/ERR	Research area Cancer
--	--------------------------------

Molecular formula **C₂₀H₁₇F₅N₂O₂**

Molecular weight **412.3532**

STRUCTURE



DESCRIPTION

ErSO-DFP is an anticipatory unfolded protein response (α-UPR) activator. ErSO-DFP has enhanced selectivity for estrogen receptor alpha-positive (ERα+) cancer cells with a wider selectivity window than ErSO. ErSO-DFP displays antitumor activity against MCF-7 in mice. ErSO-DFP can cross the blood brain barrier.

BIOLOGICAL ACTIVITY

In Vitro

ErSO-DFP (0-100 μM, 24-72 h) exhibits cytotoxicity in ERα-positive cells, IC₅₀s for MCF-7, T47D, TYS and TDG are 17 nM, 16 nM, 7 nM and 9 nM, respectively.

In Vivo

ErSO-DFP (5 mg/kg, iv, once weekly for 3 doses) exhibits antitumor activity in MCF-7 xenograft mouse models without significant toxicity.

SOLUBILITY

Soluble in DMSO : ≥ 100 mg/mL

REFERENCES

[1].Matthew W Boudreau, et al. Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer. J Med Chem. 2022 Mar 10;65(5):3894-3912.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.